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Abstract: N-(4-Bromobenzyl)-2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)benzeneamine was obtained
by condensation of N-(4-bromobenzyl)-3,1-benzoxazine-2,4-dione (N-(4-bromobenzyl)isatoic
anhydride) with 4,5-dimethyl-1,2-phenylenediamine in refluxing acetic acid. This is a rare example of
condensation of N-substituted 3,1-benzoxazine-2,4-dione with 1,2-phenylenediamine, which resulted
in the formation of a benzimidazole derivative with a moderate yield. Crystallographic studies and
initial biological screening were performed for the obtained product.
Keywords: substituted benzimidazoles; 3,1-benzoxazine-2,4-dione; isatoic anhydride;
1,2-phenylenediamine; crystallographic studies; cytotoxicity
1. Introduction
Benzimidazole derivatives are extremely popular structural scaffolds in drug design and discovery,
and provide a wide spectrum of biological activities and therapeutic effects. Their synthesis and
applications have been recently reviewed in several articles [1–8]. Their great importance in medicinal
chemistry has resulted in a large number of patent applications and has attracted great interest of the
pharmaceutical industry [9,10].
3,1-Benzoxazine-2,4-diones (isatoic anhydrides) are versatile heterocyclic intermediates used in the
synthesis of a wide range of heterocyclic scaffolds [11–13]. Based on the literature reports [14–17], the
condensation of 1,2-phenylenediamines 1 with 3,1-benzoxazine-2,4-diones 2 could lead to the formation
of substituted benzimidazole derivatives, featuring 2-(1H-benzo[d]imidazol-2-yl) benzenamines 3
as the main products, which are accompanied by various amounts of 6,7-dihydrobenzimidazo
[l,2-c]quinazolin-6-ones 4 (Scheme 1).
Such a condensation can be performed in various solvents, such as sulfolane [14], acetic
acid [15,16], or DMSO [14,17]. Fadda reported [18] that heating isatoic anhydride (2a) with
1,2-phenylenediamine (1a) or 2,3-diaminopyridine (5) in acetic acid and in the presence of sodium
acetate leads predominantly to the formation of benzoimidazolo[2,3-b]-quinazoline-6-one (6a) and
pyridooxazolo[2,3-b]quinazolin-6-one (6b), while the 2-(1H-benzo[d]imidazol-2-yl)benzenamine
(3a) and 2-(3H-imidazo[4,5-b]pyridin-2-yl)benzenamine (3b) are formed in minor amounts. The
condensation of 5,6-diamino-1,3-dimethyluracil (8) with isatoic anhydride (2a) leads to four distinct
products. The first report [14] described the formation of 8-(2-aminophenyl)theophiline (9)
and 1,3-dimethyl-11H-pyrido[4,5-b][1,4]benzodiazepine-2,4,6(1H,3H,5H)-trione (10) with 22% and
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17% yield, respectively. Furthermore, further investigation of the reaction [19] revealed formation of
two additional products: 2,6-dimethylpurino[7,8-c]quinazoline-3,5,6(2H,4H,7H)-trione (11) (12% yield)
and small amounts of tricycloquinazoline (12).
Molbank 2018, 2018, M9xx 2 of 7 
 
yield, respectively. Furthermore, further investigation of the reaction [19] revealed formation of two 
additional products: 2,6-dimethylpurino[7,8-c]quinazoline-3,5,6(2H,4H,7H)-trione (11) (12% yield) 
and small amounts of tricycloquinazoline (12). 
NH2
NH2
N
H
N
NH2
N
HO
N
N
O
N
H
O
O
N
H
O
O
OX
NH2
NH2
X
N
N
H
NH2N
O
N
N
H
X
R R
R
R
R
R
N
N
NH2
NH2O
O
CH3
CH3
N
H
O
O
O
N
NO
O
CH3
CH3
N
H
N
NH2
N
NO
O
CH3
CH3
N
H
N
H
O
N
NO
O
CH3
CH3
N
N
N
HO
N
NN
N
+ +
sulfolane or AcOH,
or DMSO 
3 39-70% 4 6-57%1 2
+ +
6a X=CH 85% 
6b C=N   70%
3a X=CH 15% 
7 C=N      30%
AcONa, AcOH,
1 2
1
2
1
2
R1=H, CH3, Cl, NO2 R2=H, CH3, Cl, Br, I
2a
1a X=CH
5   X=N
8
+
2a
sulfolane 
+
9 22% 10 17 %
11 12%
+
12
heating
rfx, 2-4 h
rfx, 30 min
 
Scheme 1. Reactions of isatoic anhydrides with aromatic 1,2-diamines. 
2. Results and Discussion 
During our continuous efforts in the investigation of various heterocyclic derivatives as 
possible antiproliferative and potentially anticancer compounds [20–22], we decided to perform a 
reaction between 4,5-dimethyl-1,2-phenylenediamine (13) and N-(4-bromobenzyl)-3,1- 
benzoxazine-2,4-dione (N-(4-bromobenzyl)-isatoic anhydride) (14) in refluxing acetic acid (Scheme 
2). We found only one example of a condensation involving of N-benzylated isatoic acid with 
1,2-phenylenediamine in the literature [14], and decided to investigate this reaction as a possible 
pathway for the synthesis of complex, biologically-relevant compounds. Thus, 4,5-dimethyl-1,2- 
phenylenediamine (13) was mixed with an equimolar amount of N-(4-bromobenzyl)-3,1- 
benzoxazine-2,4-dione (14), synthesized from 3,1-benzoxazine-2,4-dione and bromobenzyl bromide 
according to the literature procedure, [23] and the reaction mixture was refluxed in the acetic acid 
for 3 h. After the usual workup and column purification (see Materials and Methods section), we 
isolated the main product in 42% yield and identified it as N-(4-bromobenzyl)-2-(5,6-dimethyl- 
1H-benzo[d]imidazol-2-yl)benzeneamine (15). 
The identity of 15, crystallized from acetonitrile, was proven by the single-crystal X-ray 
diffraction analysis. It turned out that the investigated compound crystallizes in the orthorhombic 
space group P212121, with one molecule of the compound in the asymmetric part of the unit cell 
(Figure 1). The details of the crystallographic data and the refinement parameters are summarized 
in Table S1 (Supplementary Material). The full list of values of bond lengths, valence and torsion 
angles can be found in the Supplementary Information (Tables S2–S4). 
Scheme 1. Reactions of isatoic anhydrides with aromatic 1,2-diamines.
2. Results and Discussion
During our continuous efforts in the investigation of various heterocyclic derivatives as possible
antiproliferative and potentially anticancer compounds [20–22], we decided to perform a reaction
between 4,5-dimethyl-1,2-phenylenediamine (13) and N-(4-bromobenzyl)-3,1-benzoxazine-2,4-dione
(N-(4-bromobenzyl)-isatoic anhydride) (14) in refluxing acetic acid (Scheme 2). We found only one
example of a condensation involving of N-benzylated isatoic acid with 1,2-phenylenediamine in the
literature [14], and decided to investigate this reaction as a possible pathway for the synthesis of
complex, biologically-relevant compounds. Thus, 4,5-dimethyl-1,2-phenylenediamine (13) was mixed
with an equimolar amount of N-(4-bromobenzyl)-3,1-benzoxazine-2,4-dione (14), synthesized from
3,1-benzoxazine-2,4-dione and bromobenzyl bromide according to the literature procedure, [23] and
the reaction mixture was refluxed in the acetic acid for 3 h. After the usual workup and column
purification (see Materials and Methods section), we isolated the main product in 42% yield and
identified it as N-(4-bromobenzyl)-2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)benzeneamine (15).
The identity of 15, crystallized from acetonitrile, was proven by the single-crystal X-ray diffraction
analysis. It turned out that the investigated compound crystallizes in the orthorhombic space group
P212121, with one molecule of the compound in the asymmetric part of the unit cell (Figure 1).
The details of the crystallographic data and the refinement parameters are summarized in Table S1
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(Supplementary Material). The full list of values of bond lengths, valence and torsion angles can be
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Scheme 2. Synthesis of N-(4-bromobenzyl)-2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)benzeneamine 
(15). 
With respective average deviations from planarity of 0.034 and 0.014 Å, the benzimidazole ring 
system and the phenyl ring, which is directly attached to the above-mentioned moiety, are oriented 
at a 13.2(2)° angle. The least-squares planes defined by the non-hydrogen atoms of the adjacent 
phenyl rings of the 2-amino(4-bromobenzyl)phenyl substituent are inclined to each other at the 
angle of 84.6(2)°. 
 
Figure 1. Molecular structure of 15 with crystallographic numbering. Displacement ellipsoids are 
drawn at the 50% probability level and the H-atoms are shown as small spheres of arbitrary radius. 
The intramolecular N–H···N hydrogen bond is represented by a dashed line. 
Hydrogen atom linked to the N3-atom is involved in an intramolecular N–H···N hydrogen 
bond, where the imidazole N2-atom acts as a donor (d(D···A) = 2.705(5) Å; D˂–H···A = 138(5)°) 
(Figure 1, Table S5, the Supplementary Material). 
The packing of molecules in a crystal of the investigated compound is dominated by the 
formation of weak C–H···π and C–Br···π short contacts between the neighboring molecules (Figure 
2, Tables S6 and S7, the Supplementary Material). The full list of molecular interactions identified 
using PLATON (version 130614, Utrecht University, Utrecht, The Netherlands) [24] can be found in 
the Supplementary Material (Tables S5–S7, the Supplementary Material). 
The toxicity of the studied compound 15 was different for different cell lines studied. It was 
least effective for glioblastoma U87 cells, for which 250 μM concentration of 15 caused a decrease in 
survival only to 80% of untreated cells. Compound 15 was however toxic to other cell lines studied, 
including one epidermal cell line A431, and two non-cancer cell lines, embryonic kidney cell line 
HEK293 and telomerase-immortalized fibroblasts K21. The toxicity was similar to both the 
cancerous epidermal as well as the non-cancer cells, and, at a concentration 250 μM, the survival 
rate dropped to 30% (Figure 3). Thus, the toxicity of 15 probably depends on the characteristics of 
the organ from which the cells derive. 
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Figure 1. Molecular structure of 15 with crystallographic numbering. Displacement ellipsoids are
drawn at the 50% probability level and the H-atoms are shown as small spheres of arbitrary radius.
The intramolecular N–H···N hydrogen bond is represented by a dashed line.
With respective average deviations from planarity of 0.034 and 0.014 Å, the benzimidazole ring
system and the phenyl ring, which is directly attached to the above-mentioned moiety, are oriented at
a 13.2(2)◦ angle. The least-squares planes defined by the non-hydrogen atoms of the adjacent phenyl
rings of the 2-amino(4-bromobenzyl)phenyl substituent are inclined to each other at the angle of
84.6(2)◦.
Hydrogen atom linked to the N3-atom is involved in an intramolecular N–H···N hydrogen bond,
where the imidazole N2-atom acts as a donor (d(D···A) = 2.705(5) Å; <D–H···A = 138(5)◦) (Figure 1,
Table S5, the Supplementary Material).
The packing of molecules in a crystal of the investigated compound is dominated by the formation
of weak C–H···pi and C–Br···pi short contacts between the neighboring molecules (Figure 2, Tables S6
and S7, the Supplementary Material). The full list of molecular interactions identified using PLATON
(version 130614, Utrecht University, Utrecht, The Netherlands) [24] can be found in the Supplementary
Material (Tables S5–S7, the Supplementary Material).
The toxicity of the studied compound 15 was different for different cell lines studied. It was
least effective for glioblastoma U87 cells, for which 250 µM concentration of 15 caused a decrease in
survival only to 80% of untreated cells. Compound 15 was however toxic to other cell lines studied,
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including one epidermal cell line A431, and two non-cancer cell lines, embryonic kidney cell line
HEK293 and telomerase-immortalized fibroblasts K21. The toxicity was similar to both the cancerous
epidermal as well as the non-cancer cells, and, at a concentration 250 µM, the survival rate dropped
to 30% (Figure 3). Thus, the toxicity of 15 probably depends on the characteristics of the organ from
which the cells derive.Molbank 2018, 2018, M9xx 4 of 7 
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Figure 3. Viability plots of cell lines K21, HEK 293, A431 and U87 in response to N-(4-bromobenzyl)- 
2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)benzeneamine (15). 
3. Materials and Methods 
Commercially available chemicals were of reagent grade and used as received. The reactions 
were monitored by thin layer chromatography (TLC), using silica gel plates (Kieselgel 60F254, E. 
Merck, Darmstadt, Germany). Column chromatography was performed on silica gel 60 M 
(0.040–0.063 mm, E. Merck, Darmstadt, Germany). Melting points are uncorrected and were 
measured on a Büchi (New Castle, DE, USA) Melting Point B-540 apparatus. The 1H and 13C-NMR 
spectra, in CDCl3, were recorded at the Department of Chemistry, Warsaw University, using the 
Bruker AVANCE III HD (Billerica, MA, USA) 500 MHz spectrometer; shift values in parts per 
million are relative to the SiMe4 internal reference. The resonance assignments were based on peak 
integration, peak multiplicity, and 2D correlation experiments. Multiplets were assigned as bs 
(broad singlet), s (singlet), d, (doublet), dd (doublet of doublet), and m (multiplet). High resolution 
mass spectra were performed by the Laboratory of Mass Spectrometry, Institute of Biochemistry 
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C–Br···pi short contacts are represented by dotted lines.
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(New Castle, DE, USA) Melting Point B-540 apparatus. The 1H and 13C-NMR spectra, in CDCl3,
were recorded at the Department of Chemistry, Warsaw University, using the Bruker AVANCE III HD
(Billerica, MA, USA) 500 MHz spectrometer; shift values in parts per million are relative to the SiMe4
internal reference. The resonance assignments were based on peak integration, peak multiplicity, and
2D correlation experiments. Multiplets were assigned as bs (broad singlet), s (singlet), d, (doublet),
dd (doublet of doublet), and m (multiplet). High resolution mass spectra were performed by the
Laboratory of Mass Spectrometry, Institute of Biochemistry and Biophysics PAS, on a LTQ Orbitrap
Velos instrument, Thermo Scientific (Waltham, MA, USA). IR spectra were recorded with a Jasco 6200
(Easton, MD, USA) FT/IR spectrometer in the Laboratory of Optical Spectroscopy, Institute of Organic
Chemistry PAS (Warsaw, Poland).
A good quality single-crystal of 15 was selected for X-ray data collection at T = 100(2) K. Diffraction
data were collected on an Agilent Technologies SuperNova Dual Source diffractometer (Rigaku OD,
Wrocław, Poland) with CuKα radiation (λ = 1.54184 Å), using the CrysAlis RED software (version
1.171.38.46, Rigaku OD, Wrocław, Poland) [25]. The multi-scan empirical absorption correction
using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm, was applied [25].
The structural determination procedure was carried out using the SHELX package (version 2014/7,
University of Göttingen, Göttingen, Germany) [26]. The structures were solved with direct methods
and then successive least-square refinement was carried out based on the full-matrix least-squares
method on F2 using the SHELXL program [26]. All H-atoms linked to the N-atoms were located on a
Fourier difference map and refined as riding with Uiso(H) = 1.2Ueq(N). Other H-atoms were positioned
geometrically, with C–H equal to 0.93, 0.96 and 0.97 Å for the aromatic, methylene and methyl H-atoms,
respectively, and constrained to ride on their parent atoms with Uiso(H) = xUeq(C), where x = 1.2 for
the aromatic and methylene H-atoms, and x = 1.5 for the methyl H-atoms. All presented molecular
interactions were found using PLATON program [24]. The figures for this publication were prepared
using the Olex2 (version 1.2.6, OlexSys Ltd., Durham University, Durham, UK) and Mercury programs
(version 3.9, Cambridge Crystallographic Data Centre, Cambridge, UK) [27,28].
Crystal Data for C22H20BrN3 (M = 406.32 g/mol): orthorhombic, space group P212121 (no.
19), a = 5.70329(14) Å, b = 8.37203(17) Å, c = 37.9019(9) Å, V = 1809.75(7) Å3, Z = 4, T = 100(2)
K, µ(CuKα) = 3.163 mm−1, Dcalc = 1.491 g/cm3, 5443 reflections measured (4.6◦ ≤ 2Θ ≤ 134.2◦),
3199 unique (Rint = 0.023, Rsigma = 0.029) which were used in all calculations. The final R1 was
0.0293 (I > 2σ(I)) and wR2 was 0.0768 (all data).
The cytotoxic activity of 15 was verified against two cancer cell lines: A431 (human epidermoid
carcinoma), U87 (human glioblastoma) and two non-cancer cell lines: K21 (human fibroblast) and
HEK 293 (human embryonic kidney). One day before treatment, cells were seeded in 96-well plates at
density of 3000 cells per well and then treated with increasing concentrations (25–250 µM) of tested
compound dissolved in a complete growth medium. After 48 h of incubation, cells were assayed to
measure their viability using the alamarBlue assay (Invitrogen by Life Technologies, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Each experiment was repeated three times.
Synthesis of N-(4-Bromobenzyl)-2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)benzeneamine (15)
4,5-Dimethylphenylene-1,2-diamine (13) (830 mg, 6 mmol, 1 equiv.) was dissolved in 150 mL
of glacial acetic acid. After dissolution of the starting material, N-(4-bromobenzyl)-3,1-benzoxazine-
2,4-dione (14) (2.01 g, 6 mmol, 1 equiv.) was added and reaction mixture was refluxed for 3 h. TLC
analysis showed disappearance of the substrates and the formation of several new products. The
reaction mixture was cooled down, and acetic acid was evaporated under the reduced pressure. The
residue was co-evaporated with toluene (3 × 50 mL), then dissolved in ethyl acetate, and washed with
saturated aqueous sodium bicarbonate. The organic phase was dried with magnesium sulfate, filtrated,
evaporated with silica gel (2 g), and purified by column chromatography using hexane:ethyl acetate 9:1
v/v mixture. The first, least polar fraction, was collected and concentrated under the reduced pressure,
which led to the crystallization of the requested product 15. Yield: 1.02 g (42%). m.p. 162.5–163.5 ◦C.
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1H NMR (500 MHz, CDCl3): 9.32 (bs, 2H, 2×NH); 7.49 (dd, 1H, 3J = 7.5 Hz, 4J = 1.0 Hz, HAr); 7.43–7.37
(m, 2H, HAr); 7.31 (bs, 2H, HAr); 7.24–7.20 (m, 2H, HAr); 7.20–7.14 (m, 1H, HAr); 6.69–6.63 (m, 1H, HAr);
6.59 (d, 1H, 3J = 8.5 Hz, HAr); 4.47 (s, 2H, CH2); 2.34 (s, 6H, 2 × CH3); 13C-NMR (125 MHz, MHz,
CDCl3):151.3, 147.5, 138.6, 131.5, 130.9, 128.6, 126.5, 120.5, 115.5, 111.9, 111.5, 46.6, 20.4; HRMS (ESI):
m/z [M+H]+ calcd. for C22H20BrN3: 406.09134, 408.08929, found: 406.09129, 408.08907; IR (KBr): cm−1
3420, 3235, 3042, 2984, 2927, 1897, 1628, 1591, 1533, 1512, 1481, 1444, 1401, 1328, 1307, 1271, 1244, 1217,
1167, 1146, 1109, 1067, 1050, 1009.
4. Conclusions
The straightforward synthesis of a novel N-(4-bromobenzyl)-2-(5,6-dimethyl-1H-benzo[d]imidazol-
2-yl)benzeneamine was performed by condensation of N-(4-bromobenzyl)-3,1-benzoxazine-2,4-dione
with 4,5-dimethyl-1,2-phenylenediamine in refluxing acetic acid. The identity of product was proven
by the single-crystal X-ray diffraction analysis. The toxicity of the studied compound was similar to
both the cancerous as well as the non-cancer cells.
Supplementary Materials: The following are available online www.mdpi.com/1422-8599/2018/1/M979/s1.
Copies of the 1H-NMR, 13C-NMR, IR, HRMS-ESI mass spectra and detailed crystallographic data are available in
the supplementary information. The CCDC 1811923 (15) contains the supplementary crystallographic data for this
paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html (or from
the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk).
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